Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.
about
Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune toleranceUltrasound-assisted nonviral gene transfer of AQP1 to the irradiated minipig parotid gland restores fluid secretion.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery.Obstacles and future of gene therapy for hemophilia.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.New and improved AAVenues: current status of hemophilia B gene therapy.Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune TargetingMR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain.Unraveling the complex story of immune responses to AAV vectors trial after trial.Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy.Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants.Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery.Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in children affected by Pompe Disease.Gene therapy for hemophilia: what does the future hold?
P2860
Q27317882-E312E85E-F783-4A63-B006-0C3D222CA035Q28608009-CE1D6705-A928-4A97-90CE-0AB5A9A7EDDAQ33938435-418467B4-B9FC-4733-B287-1CF70ED90BFAQ34024890-6BEEDBE8-5DF5-4CF2-9823-F6DC5B9E8844Q38529941-4606EAE4-FD17-41CA-913D-4A956B10E07CQ38539938-39D9D606-4975-4D20-8B53-289C08357CE4Q38622440-0767D301-A364-4EF5-84AB-D772291D887FQ38874937-3015E99E-7CFF-47BB-A719-F3F2DA419845Q38903989-480638D0-65EE-45BC-A81E-8CFF87EE5288Q40073271-01074EFF-7B56-4255-A13C-7E9F71D61196Q40458807-05F49CF8-95F3-41A1-A6D4-D5C397CDEB96Q41627013-4D4A7C05-0908-47C1-B12F-08C93A42DF50Q42264139-343495AB-A0FA-448D-ACBE-C5CDD4EEBE18Q44861538-3767DC62-BA54-4834-AE99-BD276A196FA8Q45324511-7D7E374B-E015-4A83-9163-9386ABADE104Q57167448-5B866DC4-702D-458A-8705-E4E41D9603BA
P2860
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Transient and intensive pharma ...... ransfer in non-human primates.
@ast
Transient and intensive pharma ...... ransfer in non-human primates.
@en
type
label
Transient and intensive pharma ...... ransfer in non-human primates.
@ast
Transient and intensive pharma ...... ransfer in non-human primates.
@en
prefLabel
Transient and intensive pharma ...... ransfer in non-human primates.
@ast
Transient and intensive pharma ...... ransfer in non-human primates.
@en
P2093
P2860
P356
P1476
Transient and intensive pharma ...... ransfer in non-human primates.
@en
P2093
Alberto Benito
Ana Sampedro
Antonio Fontanellas
Carlos Alfaro
Carmen Unzu
Harald Petry
Ignacio Melero
Itsaso Mauleón
Jesús Prieto
Rafael Enríquez de Salamanca
P2860
P2888
P356
10.1186/1479-5876-10-122
P577
2012-06-15T00:00:00Z
P5875
P6179
1026441862